The new Express License service removes barriers to accessing this transformative gene editing technology for startups. An Express License provides fast, simple and affordable…
ERS Genomics stands as the global leader in CRISPR/Cas9 licensing, uniquely positioned at the intersection of cutting-edge science, commercial accessibility, and responsible innovation. Our…
ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement License agreement provides Université de Montréal access to CRISPR gene editing technology for use across…
CRISPR/Cas9 Prime Editing is a novel gene editing technique that utilizes a modified Cas9 protein to introduce mutations in the genome with a higher degree…
ERS Genomics and Medicines Discovery Catapult sign CRISPR/Cas9 license agreement Partnership provides Medicines Discovery Catapult access to CRISPR gene editing technology across a broad range…
A new era for environmental recovery Population growth and industrialisation has led to harmful pollution of our air, freshwater, oceans, and soil. Water quality has worsened…
CRISPR/Cas9 technology has emerged as a revolutionary tool in the field of genetics and biotechnology, allowing for precise and targeted editing of the genome of…